PT  - JOURNAL ARTICLE
AU  - Ramalan, Mansur A.
AU  - Maiyaki, Musa Baba
AU  - Gezawa, Ibrahim D
AU  - Uloko, Andrew E
TI  - Efficacy of a fixed-ratio combination of glucagon-like peptide-1 receptor agonist and basal insulin therapy for the treatment of type 2 diabetes: a protocol for systematic review and meta-analysis of randomized clinical trials
AID  - 10.1101/2024.07.18.24310630
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.18.24310630
4099  - http://medrxiv.org/content/early/2024/07/18/2024.07.18.24310630.short
4100  - http://medrxiv.org/content/early/2024/07/18/2024.07.18.24310630.full
AB  - Background Blood glucose control is a major goal of management demonstrated by many guidelines and results of clinical trials. Achieving good glycaemia is associated with reduction of the risks of cardiovascular disease. Glucagon like peptide 1 receptor agonists (GLP-1 RAs) are now important parts of many guidelines for the management of diabetes mellitus because of their cardiovascular benefit. Basal insulin in have now been combined with GLP-1 RAs in fixed ration combinations in single pens. We aim to conduct a meta-analysis and systematic review of randomized control clinical trials the evaluate the therapeutic efficacy of glucagon-like peptide-1 receptor agonists combined with basal insulin therapy in treating type 2 diabetes, using a fixed-ratio combination of the two.Method and data analysis It is anticipated that a systematic search of the literature will be conducted on the following electronic databases will be searched: The Cochrane Library, PubMed, Google Scholar, and EMBASE. We plan to include only randomized control clinical trials on GLP 1RA, fixed ratio combination of basal insulin and GLP 1RA and basal insulins alone. A validated study design-specific critical appraisal tool will be used to assess the risk of bias in individual studies. The systematic review will be performed in accordance with the JBI guideline for prevalence and incidence review. The review will be reporting following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guideline.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUnfunded studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study does not require ethical approvalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data is not yet available but will be provided when the process is completed